(Q42226312)

19 October 2017

Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. (English)

1 reference

Japanese encephalitis virus

19 October 2017

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

Japanese encephalitis

1 reference

based on heuristic

inferred from title

Japanese encephalitis vaccine

1 reference

1 reference

9

1 reference

19 October 2017

5

Yong-Qiang Deng

1 reference

19 October 2017

2

Xiao-Feng Li

1 reference

19 October 2017

4

Hong-Jiang Wang

1 reference

19 October 2017

Dong Yang

1

1 reference

19 October 2017

Qing Ye

3

1 reference

19 October 2017

Shun-Ya Zhu

6

1 reference

19 October 2017

Yu Zhang

7

1 reference

19 October 2017

Shi-Hua Li

8

1 reference

19 October 2017

language of work or name

English

0 references

publication date

4 April 2014

1 reference

19 October 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

19 October 2017

32

1 reference

19 October 2017

23

1 reference

19 October 2017

2675-2681

1 reference

Arboviral encephalitides: transmission, emergence, and pathogenesis

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Viral quasispecies evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

IC51 Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

West Nile virus core protein; tetramer structure and ribbon formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Solution structure of dengue virus capsid protein reveals another fold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Helices 2 and 3 of West Nile Virus Capsid Protein Are Dispensable for Assembly of Infectious Virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Functional Requirements of the Yellow Fever Virus Capsid Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Molecular basis for adaptation of a chimeric dengue type-4/Japanese encephalitis virus to Vero cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Passage of Dengue Virus Type 4 Vaccine Candidates in Fetal Rhesus Lung Cells Selects Heparin-Sensitive Variants That Result in Loss of Infectivity and Immunogenicity in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Neurovirulence and neuroinvasiveness of Murray Valley encephalitis virus mutants selected by passage in a monkey kidney cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Constancy and diversity in the flavivirus fusion peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Crystal Structure of the West Nile Virus Envelope Glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Crystal Structure of the Japanese Encephalitis Virus Envelope Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Characterization of the E-138 (Glu/Lys) mutation in Japanese encephalitis virus by using a stable, full-length, infectious cDNA clone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

Stability of the parainfluenza virus 5 genome revealed by deep sequencing of strains isolated from different hosts and following passage in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.074

10.1016/J.VACCINE.2014.03.074

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference